Synthetic Lethal Targeting of <i>ARID1A</i> -Mutant Ovarian Clear Cell Tumors with Dasatinib
Rowan Miller(Queen Mary University of London), Alan Ashworth(University of California, San Francisco), Holly Astley(Horizon Discovery (United Kingdom)), Sourav Bandyopadhyay(University of California, San Francisco), Josephine Joel(Horizon Discovery (United Kingdom)), Chris T. Williamson(Institute of Cancer Research), James Campbell(Proteome Sciences (United Kingdom)), John D. Gordan(University of California, San Francisco), Helen N. Pemberton(Institute of Cancer Research), Rumana Rafiq(Institute of Cancer Research), Ilirjana Bajrami(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research), Jonathan D. Moore(Horizon Discovery (United Kingdom)), Simon S. McDade(Queen's University Belfast), Asha Kigozi(Breast Cancer Now), James T. Webber(UCSF Helen Diller Family Comprehensive Cancer Center), Claire Mahoney(Horizon Discovery (United Kingdom)), Kevan M. Shokat(Howard Hughes Medical Institute), Christopher J. Lord(Institute of Cancer Research), Chris Torrance(Horizon Discovery (United Kingdom)), Rebecca S. Levin(University of California, San Francisco), Rachel Brough(Institute of Cancer Research)
Cited by 85
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k